HopeStage
Back to overview

Bipolarity studies

Topics
More filters

Bipolarity

Bipolarity involves episodes of depression and periods of elevated or irritable mood, with unusually high energy and activity.

1979studies shown
Showing 1,297-1,308 of 1,979
Other study type icon
SuspendedNCT03513549

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolarity type I

Official study title

A Postmarketing Observational Study to Evaluate the Safety of ADASUVE® (STACCATO® Loxapine for Inhalation) in Patients With Agitation Associated With Schizophrenia or Bipolar I Disorder

Recruitment is currently suspended.

In Raleigh
Bipolarity, SchizophreniaObservational studyAges 18+
Countries
United States
Sponsor
Alexza Pharmaceuticals, Inc.
Drug study icon
CompletedNCT01527448

Quetiapine in the Treatment of Postpartum Depression (PPD) in Bipolarity (BD), Type II

Official study title

An Open Label Dose Titration Study of Quetiapine XR in the Treatment of Postpartum Depression in Nonlactating Women Diagnosed With Bipolar Disorder (BD), Type II.

This study has finished and is no longer accepting participants.

In Vancouver
Bipolarity, DepressionMedication studyAges 19–40
Countries
Canada
Sponsor
BC Women's Hospital & Health Centre
Device study icon
CompletedNCT00436020

rTMS in the Treatment of Depression in bipolarity

Official study title

A Double-blind Sham Controlled Trial of rTMS in the Treatment of Bipolar Depression

This study has finished and is no longer accepting participants.

In Prahran
Bipolarity, DepressionDevice studyAges 18–70
Countries
Australia
Sponsor
Bayside Health
Drug study icon
CompletedNCT01093937

Varenicline (Champix) for Smoking Cessation/Reduction in people with Bipolarity

Official study title

A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder

This study has finished and is no longer accepting participants.

In Toronto
Bipolarity, AddictionMedication studyAges 18–65
Countries
Canada
Sponsor
Centre for Addiction and Mental Health (Hospital / academic medical center)
Drug study icon
CompletedNCT01305408

Armodafinil Treatment (150 mg/Day) for depression

Official study title

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including Birmingham
Bipolarity, DepressionMedication studyAges 18–65
Countries
United States, Argentina, Brazil, + 11 others
Sponsor
Cephalon
Drug study icon
CompletedNCT01072630

Armodafinil Treatment for depression

Official study title

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including Birmingham
Bipolarity, DepressionMedication studyAges 18–65
Countries
United States, Australia, France, + 7 others
Sponsor
Cephalon
Device study icon
CompletedNCT03287037

The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Depression in bipolarity

Official study title

To Investigate the Effect of Transcranial Direct Current Stimulation (tDCS) on Depressive Symptoms, Neurocognitive Function and Heart Rate Variability in Unipolar Depression and Bipolar Depression

This study has finished and is no longer accepting participants.

In Taipei
Depression, BipolarityDevice studyAges 20–65
Countries
Taiwan
Sponsor
Tri-Service General Hospital (TSGH)
Device study icon
CompletedNCT00186758

Transcranial Magnetic Stimulation in Depression in bipolarity

Official study title

A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression

This study has finished and is no longer accepting participants.

In Hamilton
Bipolarity, DepressionDevice studyAges 18–65
Countries
Canada
Sponsor
St. Joseph's Healthcare Hamilton
Other study type icon
TerminatedACTRN12616001328460

Targeting Functional Recovery in Mood Disorders

Official study title

A randomised controlled trial evaluating the addition of Cognitive Remediation to Interpersonal and Social Rhythms Therapy on cognitive functioning, everyday functioning, and mood morbidity in patients with severe mood disorders

This study ended early.

In New Zealand
Depression, BipolarityInterventional studyAges 18+
Countries
New Zealand
Sponsor
University of Otago

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.